By Martin Burns
A drug being developed to treat dry eye has not met its key goals in the latter stages of clinical trials.
Biopharmaceutical company Inspire carried out a six-week, randomised, placebo-controlled trial for the drug, called Proclaria.
The medicine did not reduce the symptoms of the condition to an acceptable standard in the 490-patient sample.
Inspire focuses on researching, developing and commercialising prescription pharmaceutical products for ophthalmic and pulmonary diseases and is currently reviewing the trial.
Christy L Shaffer, president and chief executive of Inspire, said: "We have provided the top-line results from this trial to our partner Allergan and we will be conducting a thorough review of the program before determining next steps, if any."
Leading eye expert Dr Tom Smith recently told the Guardian that new 30-day contact lenses contain enough moisture to prevent dry eye, but that patients already suffering from the condition should use drops and be sure to stick to the prescribed time periods for wearing them.
by Emily Tait